STADA Arzneimittel AG / AGM/EGM 10.06.2008 Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- At STADA Arzneimittel AG's Annual General Meeting, which took place today, on June 10, 2008, in Frankfurt, the Executive Board, in their remarks, confirmed the Groups positive outlook. In addition, Dr. Eckhard Brüggemann was re-elected as Chairman of the Supervisory Board of STADA Arzneimittel AG in a Supervisory Board meeting held directly after the AGM, after all shareholder representatives in the Supervisory Board were confirmed in office by the shareholders for another five years at the AGM. In addition, Karl Hertle (employee representative) was again elected by the Supervisory Board as Deputy Chairman of the Supervisory Board. In the course of the AGM, STADA's Chairman of the Executive Board, Hartmut Retzlaff, in his speech, at first elaborated on the fiscal year 2007, which was the twelfth year in a row where STADA was able to reach record levels in sales and earnings. Then Retzlaff reported in detail on the strategic and operative alignment of the Group. Here, the Executive Boards positive outlook for the business development was confirmed despite still challenging conditions. Retzlaff summarized his comments with the following words: 'The markets are becoming tougher, so are we.' The AGM endorsed all proposals of the Executive Board and Supervisory Board. Thus, a dividend of EUR 0.71 per common share an increase of 15% compared to the previous year was approved. The total dividend payments of EUR 41.6 million thus represent approx. 40% of net income. The Executive Board and the Supervisory Board were confirmed with nearly 100% approval. With similar approval, all shareholder representatives in the Supervisory Board, Dr. Martin Abend, Dr. Eckhard Brüggemann, Uwe E. Flach, Dr. K. F. Arnold Hertzsch, Dieter Koch and Constantin Meyer, were confirmed in office for further five years. The advance resolutions for the purchase and disposal of own shares as well as for capital measures found significantly sufficient majorities. The wording of todays speech of STADAs Chairman of the Executive Board Hartmut Retzlaff as well as the exact voting results for all points on the agenda can be found at STADAs website under www.stada.com/agm2008. Further information: STADA Arzneimittel AG / Corporate Communications / Stadastraße 218 / D - 61118 Bad Vilbel / Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-Mail: communications@stada.de Or visit us in the internet at www.stada.com. DGAP 10.06.2008 --------------------------------------------------------------------------- Language: English Issuer: STADA Arzneimittel AG Stadastraße 2-18 61118 Bad Vilbel Deutschland Phone: +49 (0)6101 603- 113 Fax: +49 (0)6101 603- 506 E-mail: communications@stada.de Internet: www.stada.de ISIN: DE0007251803, DE0007251845, WKN: 725180, 725184, Indices: MDAX Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf; Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-News: STADA AGM: Executive Board gives positive outlook Supervisory Board confirmed
| Source: EQS Group AG